Detalhe da pesquisa
1.
ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition.
Proc Natl Acad Sci U S A
; 121(1): e2315242121, 2024 Jan 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38154064
2.
ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression.
Proc Natl Acad Sci U S A
; 120(8): e2216479120, 2023 02 21.
Artigo
Inglês
| MEDLINE | ID: mdl-36791109
3.
ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.
EMBO J
; 40(3): e105784, 2021 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33411331
4.
Neuroblastoma xenograft models demonstrate the therapeutic potential of 177Lu-octreotate.
BMC Cancer
; 21(1): 950, 2021 Aug 25.
Artigo
Inglês
| MEDLINE | ID: mdl-34433438
5.
ATR inhibition enables complete tumour regression in ALK-driven NB mouse models.
Nat Commun
; 12(1): 6813, 2021 11 24.
Artigo
Inglês
| MEDLINE | ID: mdl-34819497
6.
Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells.
Front Oncol
; 9: 579, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31334113